The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*
Abstract
Aim: Enhancing the physiologic actions of the endogenous incretin hormones, glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide, by inhibiting dipeptidyl peptidase‐4 (DPP‐4), the enzyme responsible for their degradation, is an emerging treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the safety and efficacy of dose ranges of the DPP‐4 inhibitor saxagliptin (BMS‐477118) in patients with T2DM. Methods: In a 12‐week, multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled trial conducted at 152 out‐patient US study centres, 338 (low‐dose cohort) and 85 (high‐dose cohort) drug‐naive patients with T2DM and inadequate glycaemic control (baseline HbA1c ≥6.8 and ≤9.7%) were randomized. Following a 2‐week washout, patients received saxagliptin 2.5, 5, 10, 20 or 40 mg once daily, or placebo, for 12 weeks (low‐dose cohort). In a second cohort, patients received saxagliptin 100 mg once daily, or placebo, for 6 weeks (high‐dose cohort). The main outcome measure was saxagliptin dose response assessed as change from baseline in HbA1c following double‐blind treatment. Results: In all treatment arms, saxagliptin significantly reduced HbA1c by 0.7–0.9% from an average baseline of 7.9% vs. placebo (0.3% reduction) in the low‐dose cohort. Placebo‐subtracted HbA1c reductions were 0.45–0.63% (low‐dose cohort). Saxagliptin had significant placebo‐subtracted reductions in fasting serum glucose (14–25 mg/dl). Postprandial glucose levels at 60 min following a standard liquid meal test were reduced by 24–41 mg/dl vs. placebo. Saxagliptin was weight neutral. Adverse events were similar across treatment groups, including placebo, with a very low incidence of confirmed hypoglycaemia in saxagliptin treatment arms. Conclusions: Saxagliptin effectively improved glycaemic control in drug‐naive patients with T2DM and was generally safe, with a tolerability profile similar to placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
Metadata
- Authors
- Rosenstock, J., Sankoh, S., & List, J. F.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2008-03-18
- Volume
- 10
- Issue
- 5
- Pages
- 376-386
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1971471384
- Cited by
- 234
- References
- 4
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00876.x
- The paper
- Rosenstock, J., Sankoh, S., & List, J. F. (2008). Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00876.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.